Azilsartan medoximil

BNF:: 2.5.5.2
Status:: Grey
Decision Date:: August 2012

Comments

Formulary ARBs are the most cost-effective options.

Brown Drug Classifications

1: Lack of data on effectiveness compared with standard therapy
2: Lack of data on safety compared with standard therapy
5: Less cost-effective than current standard therapy